Replies to post #33290 on Humanigen Inc (HGENQ)

[ohm20]

Products with little indication of efficacy will be dropped on the basis of interim evaluations.

Either at interim analysis the NIH thought there might possibly be benefit. More likely they saw the results of HGENs trial and then changed their trial based on that. Except the Activ-5 trial was not initially structured to use CRP < 150 as a criteria so the addition of many CRP > 150 patients will be excluded from primary endpoint analysis.